Sagard NewGen invests in Quipment, a leading player in clinical trial equipment solutions, to support its growth ambitions and accelerate international expansion

Paris, January 14, 2026 – Sagard NewGen partners with Quipment, a leading player in clinical trial equipment solutions serving CROs and Sponsors, alongside its founders and the management team. This minority strategic investment will further strengthen the company's position as a global partner to CROs and Sponsors.

Founded in 2010 in Nancy, France, Quipment provides CROs and Sponsors with all the equipment solutions necessary to conduct their clinical trials. Quipment ensures the availability, reliability and quality of the equipment delivered for clinical trials, in order to keep investigational sites fully operational throughout the entire duration of the clinical study.

Quipment is a leading player in the fast-growing clinical trial equipment solutions market, as sponsors and CROs increasingly rely on specialist players in response to the growing complexity of clinical trial protocols, regulations, and logistics.

Quipment's unique and circular model, spanning sourcing, logistics, regulatory compliance, technical expertise, maintenance and end-of-study recovery and reuse, reduces operational and administrative burden for CROs and Sponsors, while supporting the decarbonization of the drug development value chain. The company, both a mission-driven company and B Corp certified, places sustainability and responsible growth at the heart of its operations.

With more than 200 people, Quipment operates from its Technical Service Centers in France, the United States and Japan to support the delivery of clinical trial equipment solutions to more than 110 countries worldwide.

Céline Gervais, CEO of Quipment, stated: "We are pleased to welcome Sagard NewGen as a new strategic partner. Their strong sector expertise and international network combined with the values we share - high standards, customer-centricity and sustainability - make them the right partner to support us in our growth. Together, we will dedicate our efforts to promoting a site equipment solutions model for clinical trials designed to meet the growing demand for flexibility, while ensuring operational excellence and circularity across the clinical trials value chain."

Agnès Huyghues Despointes and Bérangère Barbe, Partners at Sagard NewGen, added: "We are very proud to partner with Quipment's best-in-class management team at this new stage of the company's development. In just over a decade, Quipment has become a market reference through relentless customer focus and uncompromising quality. It is a privilege to support a company widely recognized for its operational excellence, which delivers clear value to its clients by measurably easing logistical, regulatory and administrative burdens. Quipment stands out with a truly differentiated value proposition, and we look forward to actively supporting the company and the management team to bolster Quipment's growth."

About Quipment

Founded in 2010, Quipment is a leading player in clinical trial equipment solutions – rental, sales, and inventory management – serving CROs, pharmaceutical companies, and biotechnology firms. Quipment ensures the availability, reliability, and quality of the equipment delivered for clinical trials, in order to keep investigational sites fully operational throughout the entire duration of the clinical study. We operate in more than 110 countries from our technical service centers in France, the United States, and Japan. Our circular model reduces the carbon footprint of clinical trials by limiting waste, while our flexible approach adapts to the specific needs of each project. As a mission-driven company, we place sustainability, ethical responsibility, and innovation at the heart of our operations.

The underlying force behind every clinical trial, whatever the need, Quipment makes it possible.

For more information on Quipment: https://www.quipment.com/

About Sagard NewGen

Sagard NewGen aims to support the development of leaders in the Technology and Healthcare sectors. We finance expansion strategies of European, profitable companies with sales of up to €200m that share a DNA of innovation and sustainability, through majority or minority equity investments.

Sagard NewGen is part of Sagard's international platform, which has assets under management of over $32bn across 6 strategies covering the full range of financing needs of growth companies. Leveraging flexible capital, an entrepreneurial culture and a global network, Sagard provides management teams with tailor-made support, a high value-added ecosystem and international reach, with 8 offices in Europe, North America and Abu Dhabi.

For more information: https://www.sagard.com/newgen/

Press contacts

Quipment: Nathan Jaoui, nathan.jaoui@quipment.fr

Sagard NewGen: Lucie Wallet, lucie.wallet@sagard.eu, +33 1 53 83 30 39

* * *

Parties involved in the transaction

Quipment: Pierre Malingrey, Céline Gervais, Valère Horath, Jean-François Magarinos, Nathan Jaoui

Sagard NewGen: Bérangère Barbe, Agnès Huyghues Despointes, Victoire Consten, Louis Gosselin, Eliott Leinenweber

Advisors involved in the transaction

M&A: Adviso Partners (Michaël Chicheportiche, Amanath Husain, Capucine Pochon)

Lawyers: Fidal (Brice Voillequin, Arnaud Gundermann, Antoine Elcabache); McDermott Will & Schulte (Diana Hund, Marie-Muriel Barthelet, Antoine Vergnat, Robin Lamour)

Financial due diligence: Exelmans (Stéphane Dahan, Thibault Gérald, Alexis Panquet, Nathan Grabli); Eight Advisory (Katia Wagner, Mehdi Laghmiri, Nicolas Zuccarelli, Jean-Christophe Fuzzati, Clémence Pichon)